On Friday, Shares of Coca-Cola Enterprises Inc. (NYSE:CCE), surged 12.41% to $51.08, hitting its highest level.
Coca-Cola Enterprises stated second-quarter 2015 operating income of $275 million or $289 million on a comparable basis. In the quarter, diluted earnings per share were 75 cents on a stated basis or 79 cents on a comparable basis. Currency translation had a negative impact of 18 cents on comparable diluted earnings per share.
In the second-quarter 2015, net sales totaled $1.9 billion, down 17½ percent from the same quarter a year ago. On a currency-neutral basis, net sales declined 2 percent.
“The consumer environment across our territories continues to limit retail value growth, counting the nonalcoholic ready-to-drink category,” said John F. Brock, chairman and chief executive officer. “We are managing each element of our business to maximize the value of our brands, to sustain high levels of customer service, and to improve our growth outlook.
“We are now into the key summer selling season, and our people are working diligently and effectively to utilize the strengths of our summer marketing campaigns, such as the Rugby World Cup, and our brand and package innovation initiatives to drive value growth.
“These efforts support a business-wide focus on achieving our most important aim: ongoing to build shareowner value.”
Coca-Cola Enterprises, Inc. produces, distributes, and markets non-alcoholic beverages in Belgium, continental France, Great Britain, Luxembourg, Monaco, the Netherlands, Norway, and Sweden.
Shares of XOMA Corporation (NASDAQ:XOMA), declined -9.28% to $0.73, during its last trading session, hitting its lowest level.
XOMA Corporation declared the Company will host a conference call on Thursday, August 6, 2015, at 4:30 p.m. Eastern daylight time to talk about second quarter 2015 financial results and provide an update on gevokizumab’s global clinical programs.
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company’s lead product candidate comprises gevokizumab, a proprietary humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III clinical trial for NIU and Behçet’s disease uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, autoimmune inner ear disease, and cardiovascular diseases, in addition to diseases under the neutrophilic dermatoses designation, Schnitzler syndrome, and other diseases; and various proof-of-concept studies comprising polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis.
Finally, HCP, Inc. (NYSE:HCP), ended its last trade with 1.02% gain, and closed at $38.64.
HCP declared that its Board of Directors declared a quarterly common stock cash dividend of $0.565 per share. The dividend will be paid on August 25, 2015 to stockholders of record as of the close of business on August 10, 2015.
HCP, Inc. is an independent hybrid real estate investment trust. The fund invests in real estate markets of the United States. It primarily invests in properties serving the healthcare industry counting sectors of healthcare such as senior housing, life science, medical office, hospital and skilled nursing. The fund also invests in mezzanine loans and other debt instruments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
